PRRX2 and cancer: In consequence, we hypothesize that the rs181747 CC genotype affects the binding of PRRX2 to IL-6 and that the generated IL-6 contributes to cancer development and progression via p-STAT3 and facilitates chemotactic movement of immune cells.